Causal association of cholesterol metabolism-related proteins with hepatocellular carcinoma and dysfunction-associated steatotic liver disease: a mendelian randomization study.

BACKGROUND

Dysregulation of cholesterol metabolism has been recognized as a critical driver in the pathogenesis of hepatic disorders, particularly hepatocellular carcinoma (HCC) and metabolic dysfunction-associated steatotic liver disease (MASLD). However, the causal relationships between circulating proteins involved in cholesterol homeostasis and the progression of these hepatopathologies remain insufficiently explored, warranting further mechanistic investigation.

METHODS

This study utilized Mendelian randomization (MR) to identify the role of cholesterol metabolism-related proteins in HCC and MASLD. We systematically investigated the causal associations of these proteins with HCC and MASLD and their roles in disease progression using circulating proteomic databases and bioinformatics tools. In addition, network-based drug repositioning techniques and molecular docking experiments were utilized to assess the interactions of the above biomarkers with known drugs to discover drugs with potential therapeutic effects.

RESULTS

MR analysis identified several proteins linked with significant risk for HCC and MASLD. Notably, apolipoprotein E (APOE) expression was significantly increased in tissues from HCC and MASLD patients, closely correlating with elevated disease risk. Meta-analysis demonstrated a significant causal relationship between APOE and increased risk of HCC (OR: 1.710, 95% CI 1.220-2.400; P < 0.01) and MASLD (OR: 1.490, 95% CI 1.280-1.740; P < 0.01). Additionally, network analysis revealed extensive interactions between APOE and other disease-related proteins, suggesting that APOE may contribute to liver disease progression through its influence on complex protein networks.

CONCLUSION

Our findings delineate a novel mechanistic involvement of cholesterol regulatory proteins, with APOE demonstrating pathogenic significance in both HCC and MASLD. This investigation substantially provides new insights into the molecular mechanisms of these liver diseases and highlights potential therapeutic targets.